Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESTORE: DCB for Vulnerable Plaque in ACS
NCT06365502Recruiting
- Sponsor
- Harbin Medical University
- Start
- Apr 2024
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Randomised, open-label trial (2 arms), sponsored by Harbin Medical University. Primary endpoint: Target lesion failure at 24 months. Started Apr 2024; status: recruiting.
Beyond the preview
Go deeper on NCT06365502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06365502.